Anteo Diagnostics & Sona Nanotech team up to improve lateral flow tests
Category: #health  By Pankaj Singh  Date: 2019-01-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anteo Diagnostics & Sona Nanotech team up to improve lateral flow tests

* The collaboration aims to help accelerate the development & enhance lateral flow immunoassays’ performance.

* Under the collaboration agreement, Sona’s gold nanorod tech would be merged with Anteo’s AnteoBind and several other biomarkers.

Anteo Diagnostics (Anteo), an Australian nanotechnology firm, has reportedly announced that it has signed a collaboration agreement with Canadian gold nanotechnology company, Sona Nanotech Inc. (Sona) to improve lateral flow tests’ performance.

Reports cite, the collaboration aims to help accelerate the development of lateral flow immunoassays, also called as lateral flow tests, while also attempting to enhance their performance.

According to a press release by Sona Nanotech, under the collaboration, Sona would be supplying its innovative gold nanorod technology to the Australian firm, which would be combining it with its own proprietary technology, AnteoBind™ as well as several other biomarkers such as sepsis (CRP), cardic (cTnI) markers & HCG, a renowned fertility marker utilized in home pregnancy tests.

Through the collaboration, both firms intend to develop a number of reagent sets that would greatly benefit developers of lateral flow immunoassays across the world, boost test performance, lessen the production process timeframes and promote multiplexing.

The Chief Executive Officer of Anteo Diagnostics, Christopher Parker stated that with this partnership, the company would be using crucial point of care (POC) targets in the segments of sepsis, cardiac and pregnancy testing in an effort to assess the enhancements that could be brought to the tests. Parker further added the positive results of the collaboration would encourage global lateral flow test developers to readily adopt the firms’ co-developed products.

For the record, Immunoassays are easy and relatively inexpensive to manufacture, in a market that is worth over $6 billion according to a 2018 estimate. Over two billion such tests are produced across the world on a yearly basis.

According to reports, the financial information related to the collaboration agreement has not been unveiled yet.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...